We as a large world community are facing an extraordinary challenge: keeping healthy against the threat of rapidly spreading novel Covid-19 virus. Starting with flu-like symptoms, the virus attacks the airways leading to severe breathing difficulties in the m ost vulnerable, that is, those whose im ...m unity is decreased because of various reasons: age over 65, living with chronic illness, taking im m unity reducing medicines. Rapid spread of the virus along with severity of its sym ptom s led health specialists to recommend social distancing, confinement and thorough hand washing to our governm ents who took actions to implement these guidelines.
more
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
Annals of Medicine and Surgery, 79 (2022)104033
обновленная версия от 04/10/2021
Информация о введении вакцин
– (Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer... und Spikevax® von Moderna)
more
BMJ 2020;368:m800 doi: 10.1136/bmj.m800 (Published 5 March 2020)
Reporting Period: 4 to 10 April 2020
• In collaboration with the Ministry of Youth, UNICEF started training 50 young bloggers on how to identify and respond to fake news.
• UNICEF engaged with 97 social services to enable front-line social workers to carry out community prevention work and... case management.
• With support from UNICEF, the nationwide distance learning program, “Mon école à la maison” was officially launched on TV, Radio, WebTV in addition to the free of charge SMS-based learning system.
more
The Lancet DOI: 10.1016/S2468-2667(20)30101-8
WHO declared COVID-19 to be a pandemic on March 11, 2020. The pandemic eventually reached Yemen, with the first laboratory confirmed case announced on April 10. emen has structural vulnerabilities that have developed over a protracted period of conflic...t and poor governance, and its health system has suffered the most. To prevent a total collapse of Yemen’s fragile health system, the government and the international community should act now more decisively.
more
updated version: 04/10/2021
Information about vaccine administration
Dispõe sobre orientações para identificação, investigação e manejo do evento adverso pós vacinação de miocardite/pericardite no contexto da vacinação contra a COVID-19 no Brasil
(Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та Spikevax® виробництва Moderna);
Anamnese zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
(Comirnaty® 10 μg bzw. ...30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more
Six months after its launch on 24 April, the Access to COVID-19 Tools (ACT) Accelerator has already delivered concrete results in speeding up the development of new therapeutics, diagnostics, and vaccines. Now mid-way through the scale-up phase, the tools we need to fundamentally change the course o...f this pandemic are within reach. But to deliver the full impact of the ACT-Accelerator – and ultimately an exit to this global crisis – these tools need to be available everywhere. On behalf of the ACT-Accelerator Pillar lead agencies – CEPI, Gavi, the Global Fund, FIND, Unitaid, Wellcome Trust, the World Bank, and the World Health Organization, as well as the Bill & Melinda Gates Foundation – I am pleased to share this document setting out the near-term priorities, deliverables and financing requirements of the ACT-Accelerator Pillars and Health Systems Connector. Urgent action to address these financing requirements will boost the impact of the ACTAccelerator achievements to date, fast-track the development and deployment of additional game-changing tools, and mitigate the risk of a widening gap in access to COVID-19 tools between low- and high-income countries. Delivering on this promise requires strong political leadership, financial investment, and incountry capacity building. COVID-19 cannot be beaten by any one country acting alone. We must ACT now, and ACT together to end the COVID-19 crisis.
more
Версия: 2
Дата: 10 февраля 2020 г.
Протокол посвящен выявлению и отслеживанию пациентов и их близких контактов в общей массе населения либо в условиях локального рас...ространения (например, в домохозяйствах, медицинских, образовательных учреждениях). FFX - основной протокол исследования, который должен быть использован при выявлении первоначальных лабораторно подтвержденных случаев COVID-19 в стране.
Для более целенаправленного подхода к конкретным группам и более точной оценки эпидемиологических параметров доступны три других протокола исследований
more
6th edition 13 January 2021 CR 2021.6.10, uploaded on 27 May 2021
Find eight editions: Deutsch | English | Español | Français | Italiano | Português | Tiếng Việt | Türkçe
https://covidreference.com/download
Science in 5: Episode #10 -
How important is ventilation and how does it keep you safe from COVID-19?
This global guidance provided the framework for over 100 countries to develop their NDVPs. This updated (second) version supersedes the previous version published in 16 November 2020. New information has been added on the following areas:
the COVID-19 Partners Platform;
the use of COVID...-19 simulation exercises to test deployment strategies;
the indemnity agreement and no-fault compensation programme for vaccines secured through the COVAX Facility in the Advance Market Commitment (AMC) eligible economies;
the availability and use of the WHO-UNICEF COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool;
the COVAX Facility’s humanitarian buffer that enables allocation of vaccine to cover high-risk populations in humanitarian settings;
recommendations for vaccination of pregnant and lactating women;
supplementary information on infection prevention and control (IPC) measures to be used to deliver COVID-19 vaccines safely;
the WHO licensed COVID-19 vaccines product-specific information;
use of geospatial data and digital micro plans for equitable access and delivery of COVID-19 vaccines;
lessons learned from the development of NDVPs and early experiences in COVID-19 vaccine deployment in countries; and
updated additional resources at the end of each chapter.
more
– з вакциною на білковій основі
(Nuvaxovid® виробництва Novavax)
Станом на: 15 лютого 2022 р. (даний інформаційний лист постійно оновлюється)
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Cor...ona Virus Disease 2019) (Grundimmunisierung )
– mit proteinbasiertem Impfstoff –
(Nuvaxovid® von Novavax)
Stand: 15. Februar 2022 (dieser Aufklärungsbogen wird laufend aktualisiert)
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more
As the world waits for a potential COVID-19 vaccine, we delve into how vaccines actually work. What are the different types of vaccine? How do they trigger and train the immune system, and what is the role of herd immunity?